MPN Research Foundation

Partner. Advocate. Friend. At the MPN Research Foundation, we’re committed to standing with you in the fight against polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) – the group of blood cancers collectively known as myeloproliferative neoplasms.

About Us

Providing education and resources for a better today. Investing in research for a better tomorrow.

MPNRF By the Numbers

  • $MM
    • MPN Research Funded
    • Researchers Supported
    • Projects Funded

Recent News

Pegasys users may now access resources to help with reimbursement issues through Genentech

MPN News | 9/10/19

For more information about the Genentech Patient Foundation and to learn if a patient receiving a Genentech product (such as Pegasys) is eligible to receive support, please visit www.gene.com/patients/patient-foundation or call the Patient Resource Center at 877-GENENTECH.

Read More

Patient Advocates Take Aim at Progression in Myeloproliferative Neoplasms

MPN News | 9/10/19

Through a one-year pilot grant, the MPN Research Foundation (MPNRF) will provide funding to Dr. Ann Mullally and Dana-Farber Cancer Institute's Center for Prevention of Progression (CPOP) to study the genomic basis for MPN disease progression

Read More

Imago BioSciences Granted Fast Track Designation for IMG-7289 in Myelofibrosis

MPN News | 9/6/19

Imago BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of myelofibrosis.

Read More
More News

What is Primary Myleofibrosis (MF)?

Primary Myleofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn about PMF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn about ET

What is Polycythemia Vera (PV)?

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn about PV

Patient Stories

See All Patient Stories

Debra Milner Essential Thromobocythemia (ET)

Meet Debra Milner, MDS Patient from Macclenny, FL

Age: 64 Meet Debra Milner

Tom Brennan Myelofibrosis (MF)

Meet Tom Brennan, Vietnam Veteran and Primary Myelofibrosis Patient

Age: 72 Meet Tom Brennan

Heidi Cascarano Polycythemia Vera (PV)

Meet PV patient, Heidi Cascarano from Mundelein, IL

Age: 51 Meet Heidi Cascarano

Diane Hilton Essential Thromobocythemia (ET)

Meet MPN patient Diane Hilton and read about her 31-year journey with Interferon.

Meet Diane Hilton

Ryan Tellini's Journey with Interferon Myelofibrosis (MF)

Learn about MF patient Ryan Tellini and his journey with Interferon.

Meet Ryan Tellini's Journey with Interferon

Linda Reekie Polycythemia Vera (PV)

Meet PV patient, Linda Reekie from Port St. Lucie, FL

Meet Linda Reekie

With an orphan disease, the support can be hard to find. I found that support at the MPN Research Foundation.

Juan Alderete, PV 06

Ready to do more?

Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

Get Involved Now.

Stay Connected

With your generous gift, you can change a MPN patient's prognosis.

By supporting MPN Research Foundation, you're also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.

Donate Now

Join Cancer Connect

A safe space to chat with others living with PV, ET and MF

Start here!

MPN Community Calendar

Sat, May 21st, 10am

Attend the Event

MPN Information kit

Be the first to know about what's going on in the PV, ET, and MF community.

Get the Kit